What's new


September 2011

HaploPharma will participate in BIO-Europe 2011 in Duesseldorf, Germany


HaploPharma will present their ExpressGenotyping™ technology at BIO-Europe 2011 (Oct. 31 to Nov. 02), Europe's largest partnering conference. We would be glad to arrange there a meeting with you to tell you more about our technologies and services.



September 2011

HaploPharma will participate as exhibitor in the BioJapan 2011 World Business Forum in Yokohama from October 05 - 07


HaploPharma will present their ExpressGenotyping™ technology at
BioJapan 2011, a major exposition of the world-wide bioindustry. We will exhibit at the booth B107 of the Okinawa bioindustry and will be glad to welcome you there.



August 2011

HaploPharma Tokyo office in new rooms


End of August HaploPharma’s Tokyo office will move. The new office is still close to Tokyo main station, not very far from the previous location. From beginning of September you can find us in our new rooms. Please see the updated access information here.



April 2011

Realignment of tasks and responsibilities in HaploPharma’s management


From April on the functions in HaploPharma’s management will be assigned as follows:

• Hiroshi Gushima, PhD - Chairman
• Yasuhisa Nemoto, MBA, PhD - President
• Mitsuo Itakura, MD, PhD - Chief Science Officer
• Shumpei Ishikawa, MD, PhD - Senior Scientific Advisor
• Koichi Nomoto - Director of Finance and Administration

More detailed information about HaploPharma’s management team is available in our
management section.



November 2010

HaploPharma will participate in BIO-Europe 2010 in Munich, Germany, from November 15 to 17


HaploPharma will present their ExpressGenotyping™ technology at BIO-Europe 2010, Europe's largest partnering conference.


September 2010

HaploPharma will participate as exhibitor in the BioJapan 2010 World Business Forum in Yokohama from September 29 to October 01


HaploPharma will present their ExpressGenotyping™ technology at BioJapan 2010, a major exposition of the world-wide bioindustry. We will be an exhibitor at the booth B108 of the Okinawa Industry Promotion Corporation and will be glad to welcome you there, to explain about the possibilities of our technology and our services.


August 03, 2010

HaploPharma and the University of Tokyo receive major NEDO grant


HaploPharma and the University of Tokyo, Graduate School of Medicine, gained an ‘Innovative Promotion Grant’ by the ‘New Energy and Industrial Technology Development Organization’ (NEDO) to support a joined research project for the ‘Development of high sensitive digital systems for the evaluation of drug-responsive genes’. This grant will allocate 2010 and 2011 a triple-digit million Yen amount for this collaborative R&D project.
The project aims to develop multi-purpose microfluidic chip technology for the highly sensitive detection of DNA fragments in ultra-low volumes. This technology will allow e.g. the detection of individual gene polymorphisms with high speed, sensitivity, and accuracy in very small volumes of clinical samples (e.g. peripheral blood or saliva) to predict differential drug response of individual patients.
This development is expected to advance medical treatment by improving diagnosis in early disease stages and by prediction of a patient’s likely drug response before drug application.


June 2010

Koichi Nomoto will replace Kazuo Kobayashi in HaploPharma’s supervisory board


From June 2010 K. Nomoto, who currently serves HaploPharma also as Director of Finance and Administration, will take over the duties of K. Kobayashi in the supervisory board. Mr. Kobayashi, who was board member since 2004, will devote himself more to business activities within other enterprises. HaploPharma would like to thank him for his valuable contribution during all these years.


March 25, 2010

Okinawa Development Finance Corporation invests ¥ 79.89 million in HaploPharma


Okinawa Development Finance Corporation (ODFC) announced that they have invested
79.89 million Yen in HaploPharma to promote the generation of new business areas for the company. This amount is ODFC’s highest investment in a bio-venture up to now, increasing HaploPharma’s capital to 293 million Yen. It will enable HaploPharma to extend their operation, invest in further laboratory equipment, and start new projects.
The ODFC assumes that novel health care services have a large market potential and will have in the future significant impact for the society.
HaploPharma uses its proprietary gene analysis technology to determine genetic risk factors for life style related disorders like obesity or diabetes and to utilize this information to develop tailor-made health care concepts for the individual person.


March 19, 2010

HaploPharma receives official trademark registration for “ExpressGenotyping™”


HaploPharma received the official certificate of trademark registration for ExpressGenotyping™ from the Japan Patent Office (registration number 5310960).


September 2009

HaploPharma will participate as exhibitor in the BioJapan 2009 World Business Forum in Yokohama from October 07 - 09, 2009


HaploPharma will present their ExpressGenotyping™ technology at BioJapan 2009, a major exposition of the world-wide bioindustry. You will find us as one of the exhibitors at the booth of the Okinawa Industry Promotion Corporation.



June 2009

HaploPharma will participate as exhibitor in the Bio Expo Japan 2009 trade fare in Tokyo from July 01 - 03, 2009


HaploPharma will present their ExpressGenotyping™ technology at Bio Expo Japan, Asia’s largest Bio event with 700 exhibitors and a large number of visitors. This event is widely known as a comprehensive bio event gathering all bio-related people, products, technologies and information from all across Asia. You will find us as one of the exhibitors at the booth of SPI.


October 20, 2008

HaploPharma announces agreement with Takeda Pharmaceutical about joined research to explore SNP candidates regulating individual drug response


HaploPharma Inc. announced today an agreement with
Takeda Pharmaceutical Co. Ltd.
In the research based on this agreement, HaploPharma’s ExpressGenotyping™ technology is used to explore SNP candidate regulating individual drug response.
ExpressGenotyping™ is HaploPharma’s proprietary technology developed jointly with Prof. Aburatani's group at the Research Center for Advanced Science and Technology, University of Tokyo.
ExpressGenotyping™ can efficiently and genome-widely explore and pick up candidate SNPs which may affect drug kinetics, efficacy, and toxicity in the human body.
HaploPharma believes this technology will strongly support Takeda Pharmaceutical in exploring such kind of SNPs, achieving personalized drugs, predicting adverse effects, and adjusting the optimal drug dosage based on individual genetic information.

(Original press release in Japanese can be found
here.)